In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 8, 2009, Pages 3572-3575

  Yamamoto, Kazuko ^a   Yanagihara, Katsunori ^a   Sugahara, Kazuyuki ^a   Imamura, Yoshifumi ^a   Seki, Masafumi ^a   Izumikawa, Koichi ^a   Kakeya, Hiroshi ^a   Yamamoto, Yoshihiro ^a   Hirakata, Yoichi ^b   Kamihira, Shimeru ^a   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE; GARENOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; CONTROLLED STUDY; GENE MUTATION; GENE TARGETING; GENETIC ANALYSIS; GYRA GENE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STRAIN DIFFERENCE; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; DNA GYRASE; DNA TOPOISOMERASES; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; MUTATION; STREPTOCOCCUS PNEUMONIAE;

EID: 67749127544     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00176-09     Document Type: Article

References (22)

1. Bast, D. J., D. E. Low, C. L. Duncan, L. Kilburn, L. A. Mandell, R. J. Davidson, and J. C. S. de Azavedo. 2000. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob. Agents Chemother. 44:3049-3054.
2. Blondeau, J. M., X. Zhao, G. Hansen, and K. Drlica. 2001. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45:433-438.
3. Chen, D. K., A. McGeer, J. C. de Azavedo, and D. E. Low. 1999. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 341:233-239.
4. Christiansen, K. J., J. M. Bell, J. D. Turnidge, and R. N. Jones. 2004. Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001. Antimicrob. Agents Chemother. 48:2049-2055.
5. Davidson, R., R. Cavalcanti, J. L. Brunton, D. J. Bast, J. C. Azavedo, P. Kibsey, C. Fleming, and D. E. Low. 2002. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N. Engl. J. Med. 346:747-750.
6. Dong, Y., X. Zhao, B. N. Kreiswirth, and K. Drlica. 2000. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 44:2581-2584.
7. Endimiani, A., G. Brigante, A. A. Bettaccini, F. Luzzaro, P. Grossi, and A. Q. Toniolo. 2005. Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia. BMC Infect. Dis. 5:106.
8. Fukushima, K. Y., Y. Hirakata, K. Sugahara, K. Yanagihara, A. Kondo, S. Kohno, and S. Kamihira. 2006. Rapid screening of topoisomerase gene mutations using a novel melting curve analysis for early warning of fluoroquinolone-resistant Streptococcus pneumoniae emergence. J. Clin. Microbiol. 44:4553-4558.
9. Goldsmith, C. E., J. E. Moore, P. G. Murphy, and J. E. Ambler. 1998. Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland. J. Antimicrob. Chemother. 41:420-421.
10. Grohs, P., S. Houssaye, A. Aubert, L. Gutmann, and E. Varon. 2003. In vitro activities of garenoxacin (BMS 284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones. Antimicrob. Agents Chemother. 47:3542-3547.
11. Ho, P. L., R. W. Yung, D. N. Tsang, T. L. Que, M. Ho, W. H. Seto, T. K. Ng, W. C. Yam, and W. W. Ng. 2001. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J. Antimicrob. Chemother. 48:659-665.
12. Janoir, C., V. Zeller, M. D. Kitzis, N. J. Moreau, and L. Gutmann. 1996. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob. Agents Chemother. 40:2760-2764.
13. Jones, R. N., T. R. Fritsche, H. S. Sader, and M. G. Stilwell. 2007. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values. Diagn. Microbiol. Infect. Dis. 58:9-17.
14. Jorgensen, J. H., L. M. Weigel, M. J. Ferraro, J. M. Swenson, and F. C. Tenover. 1999. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci. Antimicrob. Agents Chemother. 43:329-334.
15. Lim, S., D. Bast, A. McGeer, J. de Azavedo, and D. E. Low. 2003. Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerg. Infect. Dis. 9:833-837.
16. Linares, J., A. G. de la Campa, and R. Pallares. 1999. Fluoroquinolone resistance in Streptococcus pneumoniae. N. Engl. J. Med. 341:1546-1548.
17. Low, D. E. 2004. Quinolone resistance among pneumococci: therapeutic and diagnostic implications. Clin. Infect. Dis. 28(Suppl. 4):S357-S362.
18. Morrissey, I., and J. George. 1999. Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerase purified as recombinant proteins. Antimicrob. Agents Chemother. 43:2579-2585.
19. Pankuch, G. A., B. Bozdogan, K. Nagai, A. Tambic-Andrasevic, S. Schoenwald, T. Tambic, S. Kalenic, S. Plesko, N. K. Tepes, Z. Kotarski, M. Payerl-Pal, and P. C. Appelbaum. 2002. Incidence, epidemiology, and characteristics of quinolone-nonsusceptible Streptococcus pneumoniae in Croatia. Antimicrob. Agents Chemother. 46:2671-2675.
20. Pérez-Trallero, E., J. M. Marimon, L. Iglesias, and J. Larruskain. 2003. Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates. Emerg. Infect. Dis. 9:1159-1162.
21. Zhanel, G. G., L. Palatnick, K. A. Nichol, T. Bellyou, D. E. Low, and D. J. Hoban. 2003. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob. Agents Chemother. 47:1867-1874.
22. Zhao, X., and K. Drlica. 2002. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J. Infect. Dis. 185:561-565.